At the WIREDHealth summit, Moderna CEO Stéphane Bancel criticized the FDA’s restrictions on Covid-19 vaccine eligibility, labeling it a setback. The FDA now limits vaccine administration to individuals at high risk, a deviation from the previous recommendation of vaccination for anyone 6 months or older. Bancel highlighted the complications this poses for families with high-risk members who were previously able to easily access vaccines at pharmacies without a prescription.
Health and Human Services secretary Robert F. Kennedy, Jr., has been a vocal critic of vaccines and recently terminated a substantial contract with Moderna for an mRNA-based bird flu vaccine candidate. Kennedy’s actions have led to a shift away from mRNA Covid-19 vaccines for healthy children and pregnant women, emphasizing safety concerns such as myocarditis and pericarditis. Additionally, the administration has redirected funding away from mRNA vaccine research towards older vaccine platforms.
Despite these challenges, Moderna remains optimistic, having received FDA approval for updated Covid-19 shots and an expanded approval for its RSV vaccine. Bancel expressed confidence in the ongoing dialogue with the FDA and highlighted Moderna’s commitment to developing mRNA therapies for cancer. With 45 programs in the pipeline spanning various disease areas, Moderna anticipates 10 FDA approvals within the next three years.
Addressing concerns around vaccine safety and efficacy, Bancel emphasized the extensive testing conducted on Covid-19 vaccines, asserting that they have undergone rigorous evaluation in real-world settings involving millions of individuals. Moderna’s pioneering mRNA technology is not only shaping its infectious disease portfolio but also driving advancements in cancer therapeutics, including personalized cancer vaccines.
In the face of regulatory challenges and shifting policies, Moderna continues to forge ahead with its innovative approach to biotechnology. The company’s diverse pipeline of programs underscores its commitment to addressing unmet medical needs across cancer, rare diseases, and beyond. With a strong focus on leveraging mRNA technology across different therapeutic areas, Moderna remains at the forefront of the biopharmaceutical industry’s evolution.
Takeaways:
– Moderna CEO criticizes FDA’s restrictions on Covid-19 vaccine eligibility, citing challenges for high-risk individuals and families.
– Health and Human Services secretary Robert F. Kennedy, Jr., has shifted focus away from mRNA vaccines towards older vaccine platforms.
– Despite regulatory hurdles, Moderna remains optimistic about its pipeline, with a focus on mRNA therapies for cancer and other diseases.
– Moderna emphasizes extensive testing and safety of Covid-19 vaccines, highlighting the company’s commitment to research and innovation.
Read more on wired.com